Eye disease Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Eye disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting
Phase 1Phase 2

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Thyroid Eye Disease
Amgen88 enrolled29 locationsNCT06401044
Recruiting

Clinical and Molecular Studies in Families With Inherited Eye Disease

Inherited Eye Disease
National Eye Institute (NEI)5,000 enrolled10 locationsNCT02771236
Recruiting
Phase 3

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

Thyroid Eye Disease (TED)
Minghui Pharmaceutical (Hangzhou) Ltd258 enrolled1 locationNCT07262476
Recruiting
Phase 3

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Thyroid Eye Disease (TED)
Minghui Pharmaceutical (Hangzhou) Ltd150 enrolled1 locationNCT07257185
Recruiting

Screening for Research Participants

Eye Diseases
National Eye Institute (NEI)10,000 enrolled1 locationNCT00655096
Recruiting
Phase 4

SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease

Dry Eye Disease (DED)
Indiana University260 enrolled4 locationsNCT07243275
Recruiting

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

AsthmaVasculitisInflammatory Disease+2 more
Imperial College London120 enrolled1 locationNCT05012033
Recruiting
Not Applicable

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

Retinal DiseaseGlaucomaOptic Nerve Diseases+1 more
Duke University50 enrolled1 locationNCT06841575
Recruiting
Phase 4

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

Dry Eye Disease (DED)
Medical University of Vienna25 enrolled1 locationNCT07463950
Recruiting

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

Ocular ComplicationsGraft Versus Host Disease in EyeInflammatory Dry Eye Disease
University of Maryland, Baltimore150 enrolled1 locationNCT06874283
Recruiting

Adaptive Optics Retinal Imaging

Healthy VolunteersEye Diseases
National Eye Institute (NEI)1,000 enrolled1 locationNCT02317328
Recruiting
Not Applicable

Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

Thyroid Eye Disease
Peking University Third Hospital50 enrolled1 locationNCT07423013
Recruiting
Not Applicable

Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED

Dry Eye Disease (DED)Dry Eye Syndromes
FB Vision S.p.A74 enrolled2 locationsNCT07412860
Recruiting
Phase 1

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

SafetyTolerabilityGenSci098+1 more
Changchun GeneScience Pharmaceutical Co., Ltd.76 enrolled1 locationNCT06569758
Recruiting
Phase 4

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye

Juvenile Open Angle GlaucomaDry Eye Disease (DED)Interleukin 6+2 more
Universiti Sains Malaysia60 enrolled4 locationsNCT07396441
Recruiting
Phase 3

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

Eye DiseasesMacular Degeneration, WetSub-Macular Hemorrhage
King's College Hospital NHS Trust210 enrolled36 locationsNCT04663750
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Thyroid Eye Disease
Tourmaline Bio, Inc.81 enrolled56 locationsNCT06088979
Recruiting
Not Applicable

Impact of Tixel Treatment on Symptoms and Signs in Patients With Dry Eye Disease

Dry Eye Disease (DED)
Aston University36 enrolled1 locationNCT06615453
Recruiting

Assessment of the Ocular Microbiome in Health and Disease

Microbial ColonizationEye DiseasesOphthalmopathy
Vanderbilt University Medical Center500 enrolled1 locationNCT05414994
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

Thyroid Eye Disease (TED)
Zai Lab (Shanghai) Co., Ltd.99 enrolled27 locationsNCT07211776